Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects.

@article{Stewart2016ExtendedDS,
  title={Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects.},
  author={Michael Stewart and Harry W. Flynn and Stephen G Schwartz and Ingrid U. Scott},
  journal={Expert opinion on drug delivery},
  year={2016},
  volume={13 9},
  pages={1277-87}
}
INTRODUCTION Intraocular pharmacotherapy (vascular endothelial growth factor [VEGF] inhibitors and corticosteroids) has become first-line therapy for diabetic retinopathy (DR). A series of intraocular injections is usually required before disease modulation decreases the treatment burden in some patients, but others with chronic diabetic macular edema may require intensive longer-term therapy. AREAS COVERED Recent studies showing successful pharmacologic treatment of proliferative DR will… CONTINUE READING
Highly Cited
This paper has 17 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS